Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Benefits of rituximab for elderly DLBCL patients

Raúl Córdoba • 22 Jun 2020
EHA 2020
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Anthracycline Antibodies R-CHOP Rituximab

Raul Cordoba, MD, PhD of University Hospital Fundación Jiménez Díaz, Madrid, Spain, outlines the survival benefit of rituximab with or without anthracyclines for the treatment of diffuse large B-cell lymphoma (DLBCL) in patients over the age of 80 years. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Raúl Córdoba

The pharmacometrics of odronextamab in R/R FL & DLBCL based on the ELM-1 & 2 studies 1:30
The pharmacometrics of odronextamab in R/R FL & DLBCL based on the ELM-1 & 2 studies
Raúl Córdoba • 15 Jun 2024
Epcoritamab combined with GemOx in B-NHL: updated results from EPCORE NHL-2 1:11
Epcoritamab combined with GemOx in B-NHL: updated results from EPCORE NHL-2
Raúl Córdoba • 15 Jun 2024
Preventing and monitoring cardiotoxicities associated with treatment for hematologic malignancies 1:27
Preventing and monitoring cardiotoxicities associated with treatment for hematologic malignancies
Raúl Córdoba • 15 Jun 2024
Comprehensive geriatric assessments can aid in selecting treatment for elderly patients with CLL 2:03
Comprehensive geriatric assessments can aid in selecting treatment for elderly patients with CLL
Raúl Córdoba • 7 Oct 2023

Related Videos

A retrospective study of Pola-R-CHP versus R+DA-EPOCH in high-risk DLBCL 1:58
A retrospective study of Pola-R-CHP versus R+DA-EPOCH in high-risk DLBCL
Rahul Thakur • 8 Dec 2025
Glofitamab-GemOx versus R-GemOx in transplant-ineligible R/R DLBCL: subgroup analysis of STARGLO 2:24
Glofitamab-GemOx versus R-GemOx in transplant-ineligible R/R DLBCL: subgroup analysis of STARGLO
Haifaa Abdulhaq • 8 Dec 2025
Epcoritamab + R2 or epcoritamab maintenance in 1L FL: 3-year outcomes from EPCORE NHL-2 arms 6 & 7 2:53
Epcoritamab + R2 or epcoritamab maintenance in 1L FL: 3-year outcomes from EPCORE NHL-2 arms 6 & 7
Lori Leslie • 7 Dec 2025
Extended follow-up from a Phase I/II study of golcadomide ± rituximab in patients with R/R DLBCL 1:35
Extended follow-up from a Phase I/II study of golcadomide ± rituximab in patients with R/R DLBCL
Marc Hoffman • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals